AI assistant
DEXCOM INC — Director's Dealing 2025
Jan 31, 2025
30198_dirs_2025-01-30_3c2c1ac0-ffd3-4a3c-ad7f-d02bb5f25076.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2025-01-28
Reporting Person: Dolan Matthew Vincent (EVP, Strategy & Corporate Dev)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-28 | Common Stock | A | 3048 | — | Acquired | 43227 | Direct |
| 2025-01-29 | Common Stock | S | 1183 | $86.9144 | Disposed | 42044 | Direct |
Footnotes
F1: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.
F2: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election
under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.